Navigation Links
Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare

DENVER, July 27, 2012 /PRNewswire-iReach/ -- Snoasis Medical, Inc. formally announces the signing of a distribution agreement with Hausten Healthcare, LLC (Honolulu, HI), whereby Hausten Healthcare will distribute BioXclude™ in Japan.  While BioXclude is not approved for use by the Japanese Ministry of Health and Welfare, clinicians may legally import unapproved foreign medical products for treatment of patients in accordance with the Pharmaceutical Affairs Law. 

Hausten Healthcare is expected to begin distribution activities this coming fall.  Highly proficient in managing this unique regulatory landscape, Hausten Healthcare works in conjunction with Japanese clinicians to easily and efficiently navigate the importation process.  According to Robert Tofe, president and founder of Snoasis Medical, "we are currently seeking regulatory approval in Taiwan and South Korea, and are actively working to set up distribution in China.  Our relationship with Hausten allows access to Japan, one of the largest dental markets in the world, and punctuates our efforts to set up distribution throughout East Asia"

Amnion-chorion tissue is often referred to as the amniotic sac, the part of the placenta that encloses and protects the unborn baby through term.  This tissue is considered immunoprivileged, possesses anti-bacterial and anti-microbial properties, reduces inflammation at the wound site, and provides a protein-enriched matrix to naturally facilitate epithelialization and improve overall wound healing.  These attributes provide BioXclude with many benefits over traditional barrier membrane products used by dental professionals in guided bone and tissue regeneration procedures.

Founded in 2007, Snoasis Medical is focused on the development and commercialization of regenerative tissue and medical device products for use in dental surgery.  In 2008, Snoasis obtained the exclusive license and worldwide distribution rights to all current and future placental tissue products processed by Surgical Biologics, A MiMedx Group Company (Kennesaw, GA) for use in dentistry.  Snoasis Medical initiated commercial distribution of BioXclude in the United States in March 2010 and in Canada in September 2010.  For additional information, please visit

Hausten Healthcare, LLC is a newly formed entity focused on providing Japanese dental clinicians, institutions and patients the best possible tissue regenerative options, some of which are not currently approved by the Japanese Ministry of Health and Welfare.  Created in June 2012, Hausten Healthcare was spun out of RHC Corporation, a company focused on providing Japanese physicians and medical institutions with a greater range of medical treatment options.  

Media Contact: Eric Frank Snoasis Medical, 303-242-8075,

News distributed by PR Newswire iReach:

SOURCE Snoasis Medical
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
2. DiaTech Life Sciences Announces Medical Advisory Board
3. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
4. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
5. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
6. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
7. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
8. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
9. Live Press Briefing on Findings of Biomedical Industry CEO Survey
10. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
11. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... , November 26, 2015 ... device company specializing in imaging technologies, announced today that it ... as part of the Horizon 2020 European Union Framework Programme ... a large-scale clinical trial in breast cancer. , ... , --> --> The ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/12/2015)... , Nov. 11, 2015   Growing need ... analytical tools has been paving the way for ... determination of discrete analytes in clinical, agricultural, environmental, ... being predominantly used in medical applications, however, their ... sectors due to continuous emphasis on improving product ...
Breaking Biology News(10 mins):